SG11201909170QA - Thermogelling artificial tears - Google Patents

Thermogelling artificial tears

Info

Publication number
SG11201909170QA
SG11201909170QA SG11201909170QA SG11201909170QA SG 11201909170Q A SG11201909170Q A SG 11201909170QA SG 11201909170Q A SG11201909170Q A SG 11201909170QA SG 11201909170Q A SG11201909170Q A SG 11201909170QA
Authority
SG
Singapore
Prior art keywords
composition
artificial tears
present
thermogelling
thermogelling artificial
Prior art date
Application number
Inventor
Takeshi Yamamura
Ayaka YAMAMURO
Emi IZUKURA
Moto KIMURA
Tomohiro Otsuka
Original Assignee
Wakamoto Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wakamoto Pharmaceutical Co Ltd filed Critical Wakamoto Pharmaceutical Co Ltd
Publication of SG11201909170QA publication Critical patent/SG11201909170QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The present invention is an aqueous solution which contains two types of methyl celluloses, polyethylene glycol, polyvinylpyrrolidone, and citric acid or a pharmaceutically acceptable salt thereof. The composition of the present invention maintains a low viscosity around room temperature, but the composition is suddenly increased in the viscosity due to heat around the body temperature and has thixotropy even after gelation. 47
SG11201909170Q 2017-04-25 2018-04-25 Thermogelling artificial tears SG11201909170QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017086512 2017-04-25
JP2017249891 2017-12-26
PCT/JP2018/016854 WO2018199180A1 (en) 2017-04-25 2018-04-25 Thermogelling artificial tears

Publications (1)

Publication Number Publication Date
SG11201909170QA true SG11201909170QA (en) 2019-11-28

Family

ID=63919901

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909170Q SG11201909170QA (en) 2017-04-25 2018-04-25 Thermogelling artificial tears

Country Status (16)

Country Link
US (2) US10532026B2 (en)
EP (1) EP3593806B1 (en)
JP (2) JP6473274B1 (en)
KR (2) KR102281853B1 (en)
CN (2) CN110913867B (en)
AU (1) AU2018257301B2 (en)
BR (1) BR112019018368B1 (en)
CA (1) CA3025567C (en)
ES (1) ES2912289T3 (en)
MX (1) MX2018014935A (en)
MY (2) MY196323A (en)
PH (1) PH12019502335A1 (en)
RU (1) RU2710366C1 (en)
SG (1) SG11201909170QA (en)
TW (1) TWI733019B (en)
WO (1) WO2018199180A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019168023A1 (en) * 2018-02-28 2019-09-06 参天製薬株式会社 Ophthalmic composition comprising diquafosol and cationic polymer
WO2020175525A1 (en) * 2019-02-27 2020-09-03 参天製薬株式会社 Ophthalmic composition containing diquafosol or salt thereof, vinyl-based polymer and cellulose-based polymer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2125060C (en) * 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
JP3450805B2 (en) 2000-08-08 2003-09-29 わかもと製薬株式会社 Aqueous pharmaceutical composition
JP2003095924A (en) * 2001-07-16 2003-04-03 Wakamoto Pharmaceut Co Ltd Heat gelling artificial lacrima
GB0210794D0 (en) * 2002-05-10 2002-06-19 Chart Heat Exchangers Ltd Heat exchangers
JP4263418B2 (en) * 2002-03-18 2009-05-13 わかもと製薬株式会社 Thermal gelation artificial tears
JP4263456B2 (en) 2002-03-18 2009-05-13 わかもと製薬株式会社 Hyaluronic acid-containing thermal gelled preparation
EP1681065A4 (en) 2003-10-31 2011-12-28 Wakamoto Pharma Co Ltd Water-based composition undergoing reversible thermogelation
JP5649261B2 (en) * 2004-05-07 2015-01-07 ロート製薬株式会社 High viscosity eye drops
JP5661981B2 (en) * 2004-11-26 2015-01-28 大正製薬株式会社 Ophthalmic agent
KR20100031608A (en) 2007-06-26 2010-03-23 와카모토 세이야꾸 가부시끼가이샤 Aqueous composition

Also Published As

Publication number Publication date
EP3593806B1 (en) 2022-03-30
JPWO2018199180A1 (en) 2019-06-27
CN113332233B (en) 2022-02-25
TW201842900A (en) 2018-12-16
CA3025567C (en) 2019-10-22
AU2018257301B2 (en) 2019-10-31
KR20200020999A (en) 2020-02-26
CN110913867A (en) 2020-03-24
WO2018199180A1 (en) 2018-11-01
PH12019502335A1 (en) 2020-09-14
MX2018014935A (en) 2019-04-09
US11096889B2 (en) 2021-08-24
AU2018257301A1 (en) 2019-08-22
US20180360746A1 (en) 2018-12-20
BR112019018368A2 (en) 2020-04-07
KR102281853B1 (en) 2021-07-23
JP6736705B2 (en) 2020-08-05
JP2019104740A (en) 2019-06-27
ES2912289T3 (en) 2022-05-25
JP6473274B1 (en) 2019-02-20
EP3593806A4 (en) 2020-03-25
MY196565A (en) 2023-04-19
KR102083253B1 (en) 2020-03-02
US20200121592A1 (en) 2020-04-23
CN110913867B (en) 2021-06-11
MY196323A (en) 2023-03-24
CN113332233A (en) 2021-09-03
TWI733019B (en) 2021-07-11
US10532026B2 (en) 2020-01-14
BR112019018368B1 (en) 2021-03-02
EP3593806A1 (en) 2020-01-15
KR20190110624A (en) 2019-09-30
CA3025567A1 (en) 2018-11-01
RU2710366C1 (en) 2019-12-26

Similar Documents

Publication Publication Date Title
MX2018010788A (en) Ophthalmological composition.
PH12019500579A1 (en) Pharmaceutical composition
BR112018075140A2 (en) composition in the form of an injectable aqueous solution, and single dose formulation at a pH of 7 to 7.8
EP2996172A3 (en) Biocompatibility of biomedical energization elements
MX2019015311A (en) Cannabidiolic acid esters compositions and uses thereof.
MX2020005942A (en) Oral thin film with high active agent loading.
NZ745811A (en) Hemisulfate salt of 5,10-methylene-(6r)-tetrahydrofolic acid
MY173573A (en) Pyridin-4-yl derivatives
MX2020006596A (en) Hydroxyisoxazolines and derivatives thereof.
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
GEP20237486B (en) Formulations of copanlisib
NZ738197A (en) Antihypertensive agent
SG11201909170QA (en) Thermogelling artificial tears
MX2021008072A (en) Prebiotic composition and its use.
CA3003108A1 (en) Storage stable composition comprising rifaximin alpha
MX2019010218A (en) Pyrazole derivatives as bromodomain inhibitors.
MX2015012211A (en) Ionic liquids and uses thereof.
BR112017020216A2 (en) "aqueous composition".
GEP20196957B (en) Crystalline forms of s-acetyl glutathione, their reparations and uses in pharmaceutical and nutraceutical formulations
PH12021550090A1 (en) Composition comprising glycyrrhizin and cosmetic and pharmaceutical uses thereof
IL253370A0 (en) Compositions comprising hydroxycinnamic acid and related conjugates, analogues and derivatives, and methods of use thereof
MX2019015869A (en) New oral formulations of belinostat.
PH12016502527B1 (en) Stabilized desmopressin
PH12019501946A1 (en) Liquid composition containing pradofloxacin
SG10201810362SA (en) Anti-allergic agent, agent for improving allergic diarrhea and pharmaceutical composition